Approval times for supplemental indications for recombinant proteins.
Gosse
M E
ME
Tufts Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA.
Nelson
T F
TF
D001709:Biotechnology / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D005818:Genetic Engineering; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D009965:Orphan Drug Production / Q000331:legislation & jurisprudence; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D011994:Recombinant Proteins